Saturday 17 October 2026 Export RNLXY’s income statement to Excel — free account

Renalytix plc - Sponsored ADR

RNLXY Healthcare Health Information Services

Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024. Operating cash flow growth for three consecutive years.

3.50 0.11 +3.24%

Follow RNLXY

Alert me

Market cap: $17.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: −15.64
Beneish M: −4.68
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 17.18

Revenue 2.36

Net Income (27.73)

Free Cash Flow (22.71)

Net Debt (1.49)

Current Ratio 2.43

Debt/Equity (5.99)

P/E ratio 0.00

Fwd P/E —

P/S ratio 3.13

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 71.40%

Next Y EPS Growth 40.60%

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.82%

10-year low 10-year high

EV/Sales against its own 10 years 10.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	41	25	5	4
Receivables	1	1	1	1
Inventory	—	—	0	0
Other	—	—	—	—
	45	27	7	6

	2022	2023	2024	2025
Payables	2	3	8	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	12	16	12	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	0.34%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’25	1	—	—	—	3
’24	0	1	1	1	2
’23	1	1	1	1	3
’22	0	1	1	1	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’25	(4)	(6)	—	—	(18)
’24	(10)	(8)	(5)	(8)	(30)
’23	(7)	(8)	(10)	(9)	(34)
’22	(10)	(14)	(7)	(14)	(46)
’21	(10)	(8)	(5)	(5)	(28)
’20	(2)	(3)	(3)	(2)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’25	(4)	(6)	—	—	(18)
’24	(10)	(8)	(5)	(8)	(30)
’23	(7)	(8)	(10)	(9)	(34)
’22	(11)	(14)	(7)	(14)	(47)
’21	(11)	(9)	(5)	(5)	(30)
’20	(2)	(3)	(3)	(3)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’25	(2.24)	—	—	—	(3.75)
’24	(5.36)	(4.36)	(3.96)	(7.32)	(21.00)
’23	(7.99)	(6.97)	(7.07)	(5.50)	(27.54)
’22	(7.00)	(10.60)	(10.16)	(2.90)	(30.66)
’21	(5.45)	(6.33)	(6.09)	(6.84)	(24.72)
’20	(1.27)	(3.93)	(0.62)	(2.52)	(8.33)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	6,191.88	8,118.75	656.25	190.00	75.00	3.60	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	11,250.00	22,318.75	11,141.25	2,523.75	1,500.00	202.50
People
People	Employees	—	—	—	14	19	54	102	—	—	46
	Revenue/emp, $m	—	—	—	0.00	0.00	0.03	0.03	0.00	0.00	0.07
Income, $m
Income, $m	Revenue	—	—	—	—	—	1	3	3	2	3
	Gross margin, %	—	—	—	0.00	0.00	42.45	29.43	21.16	8.70	40.00
	EBT	—	—	0	(42)	(10)	(35)	(45)	(46)	(45)	(22)
	EBT margin, %	—	—	0.00	0.00	0.00	(2,369.95)	(1,523.60)	(1,340.14)	(1,978.26)	(726.67)
	Net income	—	0	0	0	(10)	(35)	(45)	(46)	(45)	(22)
	Depreciation	—	—	—	0	0	0	0	1	3	—
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	1.04	2.04	2.05	1.06	0.51
	Earnings	—	—	(0.01)	(49.69)	(8.33)	(24.72)	(31.07)	(27.54)	(21.00)	(3.75)
	Cash flow	—	—	(0.01)	(7.23)	(8.06)	(19.86)	(31.52)	(20.58)	(13.75)	(3.07)
	Capex	—	—	0.00	(0.36)	(1.04)	(1.06)	(0.45)	0.00	0.00	0.00
	Free cash flow	—	—	(0.01)	(7.60)	(9.10)	(20.93)	(31.97)	(20.58)	(13.76)	(3.07)
	Book value	—	—	(0.01)	10.05	13.47	49.98	21.00	4.21	(4.15)	(1.20)
	Shares, m	—	—	28	1	1	1	1	2	2	6
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	17,226.65	751.29	888.21	147.79	103.45
	P/B	—	—	—	—	—	385.88	72.90	433.84	0.00	0.00
	EV/Sales	—	—	—	—	—	17,185.99	739.96	883.16	147.31	102.82
	EV/FCF	—	—	—	—	—	(919.43)	(47.17)	(86.49)	(11.23)	(10.52)
Cash, $m
Cash, $m	Operating cash flow	—	—	0	(6)	(10)	(28)	(46)	(34)	(30)	(18)
	Capex	—	—	—	0	(1)	(2)	(1)	—	0	—
	Free cash flow	—	—	0	(6)	(11)	(30)	(47)	(34)	(30)	(18)
Balance, $m
Balance, $m	Working capital	—	—	0	8	12	60	33	11	(5)	1
	Total debt	—	—	0	—	0	—	8	8	4	8
	Net debt	—	—	0	(9)	(14)	(65)	(34)	(17)	(1)	5
	Shareholders’ equity	—	—	0	9	16	71	31	7	(9)	(7)
Returns, %
Returns, %	ROA	—	—	(921.96)	0.00	(64.38)	(69.83)	(70.39)	(113.04)	(241.19)	(309.09)
	ROIC	—	—	0.00	0.00	(363.82)	(314.98)	0.00	0.00	0.00	0.00
	ROE	—	—	(10.02)	(1,031.32)	(80.48)	(79.49)	(88.72)	(242.76)	4,476.14	255.00

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2025 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ONMD OneMedNet Corporation	$28.6M	— (loss-making)	—	+88.39% (above 0%: growing)	n/m	+14.05% (above 0%: growing)	(193.49%)	(774.32%)	Compare
BEAT HeartBeam, Inc.	$24.3M	— (loss-making)	—	—	n/m	−1.24% (below 0%: shrinking)	—	0.00%	Compare
RNLXY Renalytix plc - Sponsored ADR	$17.2M	— (loss-making)	—	+13.73% (above 0%: growing)	n/m	+17.96% (above 0%: growing)	19.16%	(783.91%)
BFRG Bullfrog AI Holdings Inc.	$9.9M	— (loss-making)	—	+2,054.00% (above 0%: growing)	n/m	−5.67% (below 0%: shrinking)	49.63%	(658.82%)	Compare
ETAOF ETAO International Co., Ltd.	$9.8M	— (loss-making)	—	—	n/m	+37,595.70% (above 0%: growing)	—	0.00%	Compare
HCTI Healthcare Triangle, Inc.	$7.4M	0.0×	— (loss-making)	+158.38% (above 0%: growing)	n/m	+67.48% (above 0%: growing)	22.48%	(44.28%)	Compare
MGRX Mangoceuticals, Inc.	$7.1M	— (loss-making)	—	−59.07% (below 0%: shrinking)	n/m	+79.27% (above 0%: growing)	64.24%	(1,501.45%)	Compare
HLTHQ Cue Health Inc.	$6.9M	— (loss-making)	— (loss-making)	−87.19% (below 0%: shrinking)	n/m	+50.55% (above 0%: growing)	(90.14%)	(792.13%)	Compare
ZCMD Zhongchao Inc.	$6.2M	— (loss-making)	—	+20.44% (above 0%: growing)	−550.00% (below 0%: shrinking)	+191.85% (above 0%: growing)	41.67%	0.00%	Compare
Median of peers	$8.6M	—	—	+54.42%	—	+59.02%	32.08%	(351.55%)

All 51 Health Information Services stocks →

Renalytix plc - Sponsored ADR (RNLXY) key facts

Strength: Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024.
Renalytix plc - Sponsored ADR (RNLXY) is a Health Information Services company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, RNLXY traded at $3.50, a market capitalization of $17.2 million.
Return on equity was 255.0% and debt-to-equity -5.99.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −15.64 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.